- Berger Montague said it is investigating whether Hims & Hers’ board breached fiduciary duties related to private health-data sharing with advertisers, deceptive billing and difficult subscription cancellations.
- CEO Andrew Dudum said the FTC lawsuit misunderstands Hims & Hers’ business and defended compounded GLP-1 sales as a way to lower weight-loss treatment prices.
- Hims & Hers reported Q2 revenue growth of nearly 40% to $753 million and added 300,000 subscribers, but adjusted gross margin fell to 64% from 76% and free cash flow was negative $68 million.